LiverRight and Aegle Medical Solutions, LLC have announced a strategic partnership aimed at expanding access to non-invasive liver assessment, specialist interpretation, diagnosis, and ongoing liver care for patients across the United States. The collaboration brings together Aegle Medical's advanced liver assessment technology and support services with LiverRight's national virtual liver clinic, creating a more connected pathway for healthcare organizations to move patients efficiently from liver disease identification to specialist interpretation and longitudinal management.
For physicians, health systems, and independent practices, the partnership is designed to simplify the establishment or expansion of comprehensive liver disease programs without building every component internally. Aegle Medical provides a consultative approach to technology evaluation, implementation, training, and ongoing support, while LiverRight offers same-day interpretation services for liver elastography studies and same-week virtual access to its hepatology clinicians. LiverRight's Liververse™ referral system coordinates bloodwork, patient-reported outcomes, available imaging, diagnosis, and longitudinal disease management. This model aims to bring advanced liver assessment closer to communities where patients already receive care, improving access to liver specialists and creating a more efficient pathway from risk identification to appropriate ongoing care.
The partnership also highlights the Mindray Hepatus-Series Transient Elastography Diagnostic Ultrasound Systems, which Aegle Medical distributes exclusively in the United States. The Hepatus platform introduces Visualized Transient Elastography (ViTE), a next-generation breakthrough that integrates real-time B-mode ultrasound visualization directly into the elastography examination. Unlike conventional transient elastography platforms that rely primarily on measurement data, ViTE enables operators to see liver anatomy, identify optimal measurement locations, and visually guide each acquisition while obtaining quantitative liver stiffness and attenuation measurements. This evolution combines the efficiency of transient elastography with the clinical confidence of real-time ultrasound visualization in a single examination.
Brandon Tudor, CEO of LiverRight, stated, "Aegle Medical Solutions is helping hospital systems and independent practices nationwide address the significant number of adults living with undiagnosed liver disease in the United States. By working together, we help practices bring advanced liver assessment into the outpatient setting, provide timely specialist interpretation, and move patients into the appropriate diagnostic and care workflow with greater efficiency." Michael McTighe, President & CEO of Aegle Medical Solutions, added, "This strategic partnership with LiverRight represents an important step forward in our shared vision of expanding access to liver disease detection and care within the communities we serve." He continued, "We believe this model can be particularly valuable for communities where access to hepatology specialists may be limited. Our goal is to help providers identify liver disease earlier, improve access to specialist expertise and ultimately create a better experience for both patients and clinicians."
The Hepatus platform also provides liver stiffness measurement (LSM) for fibrosis assessment and Liver UltraSound Attenuation (LiSA) for quantitative assessment of hepatic steatosis. The Hepatus 6 further expands capabilities by combining these with diagnostic ultrasound imaging, enabling abdominal imaging, Doppler, spleen stiffness assessment, and intestinal ultrasound depending on configuration. LiverRight has its own hepatologists and advanced practice providers licensed across all 50 U.S. states, supporting adult patients with conditions including MASLD/MASH, alcohol-associated liver disease, hepatitis B and C, primary biliary cholangitis, primary sclerosing cholangitis, autoimmune hepatitis, and liver cancer diagnosis. The strategic relationship gives health systems, GI and hepatology practices, and independent providers a scalable approach to expanding liver services under their own brand.
